NEW Report about CofixRX (Virucidal Assay) against SARS-CoV-2 viruses and its variants – by UtahState University

A renewed and updated independent in-vitro study performed by one of the most reputable research institutes in the country, specifically targeting the CofixRX Nasal Spray efficacy against the SARS-Cov-2 virus and its most recent and highly infectious variants, Delta and Omicron. The study also certifies the unrelenting undiminishable efficacy and strength of the product 6 and 24 hours after its first application.